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Early survival following myocardial infarction (MI) has
improved significantly over the past 20 years, due in part to
medical treatments including thrombolysis, aspirin and
beta-blockade. Now, more MI survivors are at risk from the
subsequent development of heart failure (1). The clinical
entity of heart failure in such patients is a problem and one
to which much research attention, both preventive and
palliative, has been directed recently.
Heart failure following MI results from changes in
ventricular size, shape and structure due to myocardial
damage. This process has been termed ventricular remod-
eling and though initially adaptive and compensatory, it
becomes deleterious over time causing progressive ventric-
ular dysfunction.
See page 2047
Within days of acute coronary occlusion and MI, remod-
eling may begin with infarct expansion and compensatory
hypertrophy of the noninfarcted regions. This is accompa-
nied or followed by a phase of global ventricular dilatation
occurring over months and involving both infarcted and
noninfarcted segments. These processes establish a new
pressure-volume relationship in the damaged ventricle, pre-
serving stroke volume despite a reduction in left ventricular
(LV) ejection fraction and tending to continue the ventric-
ular dilatation.
Central to the process of remodeling and the pathophys-
iology of heart failure is activation of the renin-angiotensin-
aldosterone and sympathetic nervous systems. This occurs
early following acute MI, and the resultant vasoconstriction,
volume expansion and ventricular dilatation increases wall
stress, which is a major stimulus for continued ventricular
remodeling.
The degree of remodeling after MI can be determined
clinically, by assessing LV size and function using echocar-
diography or radionuclide ventriculography. Left ventricular
volumes, and particularly end-systolic volume, are prognos-
tically important, more so than LV ejection fraction or
infarct size (2). Prognosis is most favorable in patients
without LV dilation, and thus prevention of remodeling
after MI is a major therapeutic objective to improve long-
term outcomes.
Appropriately timed interventions such as thrombolysis
or therapeutic alterations to reduce LV loading conditions
can favorably influence LV remodeling early and late after
infarction. Initial measures to limit infarct size using throm-
bolysis showed the degree of infarct artery perfusion after
MI to be more important than infarct size itself in predict-
ing volume change. Occlusion of the infarct-related artery
(IRA) was associated with greater LV volumes and a more
spherical LV shape despite minor differences in ejection
fraction (3). Treatment to reperfuse the IRA should there-
fore be considered the most effective immediate strategy to
prevent LV remodeling and improve subsequent mortality
and morbidity (4,5).
Additional measures to limit infarct size and reduce
remodeling include the use of nitroglycerin or angiotensin-
converting enzyme (ACE) inhibitors. Nitroglycerin can
limit infarct size, infarct expansion and remodeling, but
large-scale studies have not demonstrated clear mortality
benefit following acute MI (6,7). However, clinical trials
have shown that ACE inhibitors can improve survival in
patients with reduced LV systolic function or heart failure
after MI (8,9). Initial evidence that ACE inhibitors atten-
uated LV dilatation after MI came from studies in selected
patients with LV impairment, anterior MI or Q-wave MI
(10–12). However, evidence that ACE inhibitor treatment
improves LV remodeling in patients with a patent IRA and
in studies in which high proportions of patients received
thrombolysis has been conflicting (13,14). Benefit from
ACE inhibitor treatment thus seems to be greatest in
patients at higher risk of LV dilatation due to more
extensive infarction, particularly those with anterior or
Q-wave infarction with an occluded IRA.
The potential for progressive ventricular dilatation exists
from the time of acute coronary occlusion and infarction.
Very early treatment may be most effective but will not
benefit all patients and is not without hazard. Large inter-
vention trials of ACE inhibitor treatment early and nonse-
lectively after MI showed that approximately one third of
the modest survival benefit evident at 35 days was apparent
in the first 24 h following intervention (6,7). In CONSEN-
SUS II, however, no mortality benefit was shown when
ACE inhibitor treatment was given very early after MI. A
possible proischemic effect resulting from hypotension sec-
ondary to the treatment was suggested as the likely mech-
anism offsetting any benefit (15).
Although more than 120,000 patients with MI have been
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involved in clinical trials using ACE inhibitors, important
questions remain regarding the use of these agents. Optimal
timing of ACE inhibitor treatment after MI and the exact
mechanisms of benefit have not been completely resolved.
In this context, the article by de Kam et al. (16) provides
useful guidance. This group reports a meta-analysis com-
bining three trials in which ACE inhibitor treatment was
given very early after anterior MI in patients also receiving
thrombolysis, aspirin and beta-blockade. Echocardiography
was used to assess LV volume change over the three months
following MI. Left ventricular dilation was not significantly
affected by ACE inhibitor treatment overall. However, in
the subgroup of patients who had “bedside” clinical evidence
of lack of reperfusion, LV dilation was significantly atten-
uated. This article provides additional evidence supporting
increased benefit of ACE inhibitor treatment in certain
patient groups at high risk of developing LV dilation. The
safety of adding ACE inhibitor treatment to the cocktail of
drugs currently routinely recommended following acute MI,
despite relatively low blood pressure, has also been con-
firmed by this article.
Previously, very early initiation of ACE inhibitor treat-
ment for all patients without significant hypotension after
MI, with a policy of subsequent review of treatment, has
been recommended (17). Despite this recommendation, a
more selective approach has often been favored as more
practical. This meta-analysis helps further to identify high
risk subgroups of patients who will benefit most and should
be treated with an ACE inhibitor without undue delay. A
more targeted policy is now supported for the commence-
ment of ACE inhibitor treatment as soon as practical in
patients with large or anterior infarcts, or with clinical
evidence of lack of reperfusion, as well as in patients with
significant LV impairment or heart failure. This “selective”
approach to ACE inhibitor treatment can be reviewed later.
Patients with persisting LV dysfunction will require con-
tinuation of ACE inhibitor therapy while those with normal
LV function and a favorable risk profile following the acute
event might discontinue treatment. However, beyond con-
siderations of LV remodeling, the recent demonstration of
clear benefits from ACE inhibitor treatment in high risk
patients with atherosclerotic disease but preserved LV
function (18) indicates additional cardiovascular protective
effects from ACE inhibitor treatment and extends the
indications for such treatment further.
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